I reminded myself that in the interims published end September they correctly forecast they would get €30m in cash.
Too bad we will have to wait 3 months-perhaps more-to get the 2023 accounts to see if H2 cash burn was less than the £14m in H2 |
31.3 m euros or pounds |
Also there could be a bit of selling if those that bought in the raise decide to get out - though having said that the take up from PIs was insignificant.
What we really need though is some clinical data showing the superiority of their core products and signs of traction with customers.. Must be due an update on both. |
Yes good news, though without wishing to be a party pooper, I note that Cavendish have forecast £31.3m inflow from disposals this year. Perhaps there are other disposals planned or it is just that the cash proceeds are less than forecast. |
£30m in cash - outstanding |
good news, hope all goes well with the trial, GLA |
I expect they will cut and paste your quote Dr B. I don't see anything from the takeover panel yet but maybe it is in Spanish. The Chinese company is already operating in Europe with no bad press so hopefully a clean run through. |
Probably due some sort of trading update in the next few weeks - could hopefully get progress on the clinical trials and sale of the consumables business too. Key though will be sales of their core products - lets hope its upfront and open rather than "in line with expectations based on adjusted projections" or other such management guff.
Only a 2% holding for me now, partly through selling down but mostly through poor performance |
And with more than a nod to the Chinese markethttps://www.linkedin.com/posts/creo-medical_lunarnewyear-chinesenewyear-anythingispossiblewiththerightapproach-activity-7290186922927259648-JaoW?utm_source=share&utm_medium=member_ios |
Good to see gold standard Fujifilm giving some more credibility to Creo tech in their US training programhttps://www.google.com/search?q=creo+medical&sca_esv=15ea5b57039dcf13&rlz=1CDGOYI_enGB1116GB1116&hl=en-GB&prmd=nmiv&sxsrf=AHTn8zrxi08OomfQPuwLIlYRhskBJJe8hw:1738131985611&source=lnt&tbs=qdr:d&sa=X&ved=2ahUKEwiqycycppqLAxWwXUEAHbPdHFYQpwV6BAgHEAo&biw=414&bih=720&dpr=2#vhid=45nFsOTlp0NkjM&vssid=_GcqZZ6mTD4eFhbIP3Z2Z6Ac_44 |
Got a plug from Motley Fool, a pathetic almost embarrassing amount of research but any publicity......https://www.fool.co.uk/2025/01/26/2-penny-stocks-with-growth-potential-to-consider-buying-in-2025/ |
https://x.com/rckhlldd/status/1881445106097557660?s=46 |
https://x.com/rckhlldd/status/1881444820851544239?s=46 |
https://x.com/rckhlldd/status/1881444055487275297?s=46 |
 Creo Medical Group plc("Creo" the "Company" or the "Group") First robotic-guided lung ablation cases commenceas part of Intuitive collaboration agreement Robotic-guided microwave ablation of cancerous lung tissue now being undertaken at two UK sites Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the first robotic-guided microwave ablation of cancerous lung tissue cases have commenced at a leading UK hospital (the "Hospital"). As announced in July 2024, the Company amended its multi-year collaboration with Intuitive and this latest robotic-guided microwave ablation procedure for lung cancer is the first clinical case using Intuitive's Ion Endoluminal System and Creo's MicroBlate Flex ablation device to take place under the amended terms of the agreement at the Hospital. The Hospital is now the second site to have performed microwave ablation procedures for lung cancer. The first UK site to perform such procedures was the Royal Brompton Hospital as part of an ongoing clinical study1 conducted by Professor Shah. The Pioneer Programme will continue to roll-out throughout 2025 to support the collection of clinical evidence ahead of the sites entering a commercial phase, and the Company expects the number of procedures performed to grow in the current year. Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted that this first clinical site under the Pioneer Programme, representing a second UK clinical site, has started clinical practice and successfully completed their first robotic-guided lung cancer ablation procedure using Creo's MicroBlate Flex alongside Intuitive's Ion Endoluminal System. With both the clinical study at the Royal Brompton and this site as part of the clinical Pioneer Programme, we now have two UK hospitals undertaking these procedures. These sites, under the amended collaboration agreement with Intuitive, will provide us with the clinical evidence needed to support the wider commercialisation of the MicroBlate Flex device. We look forward to updating shareholders on our progress." |
https://youtu.be/nqXA5nEKqbc?si=DVE3Iemnr2tUC7t- |
https://youtu.be/ZiIN9tXJZBI?si=XxyrlTNFPb8zsrnX |
I am super confident with the people in charge here. Their track record is outstanding. This will come good. |
Apologies Pro trader, yes I sound like some nasty old woman. Actually love the tech and provides a good investment and trading opportunity if all goes to plan. I just wish management wouldn't treat it like they were running a hedge fund on the remuneration. |
https://youtu.be/7mvoAoD701o?si=vWQ7WPrEHrKA8Nkw |
What's not to like Bloomberg? Maybe the fact they have been trying to grow the market/sales of speedboat for years now and failing at every metric, whilst having management paying themselves obscene amounts of money. I can't reconcile that. |
https://youtu.be/oaT5n9VqkPs?si=cXviq07D-OX5bbXc |
What's not to like |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
